Orforglipron vs Oral Wegovy: Head-to-Head Pill Comparison
An independent, side-by-side comparison of orforglipron and oral-wegovy for GLP-1 weight loss programs — pricing, medications, protocols, and patient experience.
In-Depth Comparison
By Telehealth Ally Editorial Team · Last updated March 28, 2026
Orforglipron vs Oral Wegovy: Head-to-Head Pill Comparison
Oral Wegovy is FDA-approved for weight management. Orforglipron (pending FDA approval, PDUFA April 10, 2026) will join it if approved, and patients finally have a real choice between oral options. Orforglipron (Eli Lilly) is a small-molecule pill with no food restrictions at $149/month. Oral Wegovy (Novo Nordisk) is the pill form of semaglutide — the same active ingredient as injectable Wegovy — at $199-$299/month, but it requires a 30-minute fasting window each morning.
Here's how they compare across price, efficacy, side effects, convenience, and insurance coverage — so you can make an informed decision with your provider.
Quick Comparison Table
| Factor | Orforglipron | Oral Wegovy |
|---|---|---|
| Manufacturer | Eli Lilly | Novo Nordisk |
| Type | Small-molecule GLP-1 agonist | Peptide-based semaglutide |
| Mechanism | GLP-1 receptor agonist | GLP-1 receptor agonist |
| Frequency | Once daily | Once daily |
| Food restrictions | None | 30-min fasting, limited water |
| Weight loss (trials) | ~12.4% body weight (ATTAIN-1, 36mg) | ~16.6% body weight (OASIS 4, 25mg) |
| Nausea rate | ~59% | ~47% |
| Vomiting rate | ~14% | ~31% |
| Self-pay price | $149/mo | $199-$299/mo |
| Insurance coverage | Growing (new drug) | Good (established brand) |
| Medicare coverage | Check plan | Yes (covered under TROA) |
| Available since | April 2026 | January 2026 |
| Take with food? | Yes | No (empty stomach required) |
| Time of day | Anytime | Morning recommended |
The short version: Oral Wegovy produces more weight loss in trials (~16.6% vs ~12.4%). Orforglipron is cheaper and far more convenient to take — no fasting, no timing restrictions. The right choice depends on whether you prioritize maximum efficacy or daily convenience and cost savings.
What does the evidence show for orforglipron vs oral Wegovy weight loss?
Oral Wegovy delivers roughly 4 percentage points more weight loss than orforglipron based on available trial data. That gap is real, though the trials ran different durations — making a precise comparison difficult without a head-to-head study.
| Metric | Orforglipron (ATTAIN-1) | Oral Wegovy (OASIS 4) |
|---|---|---|
| Trial duration | 48 weeks | 68 weeks |
| Population | Adults with obesity, no diabetes | Adults with obesity, no diabetes |
| Average weight loss (top dose) | ~12.4% body weight (36mg) | ~16.6% body weight (25mg) |
| Patients losing 5% or more | ~69% | ~84% |
| Patients losing 10% or more | ~47% | ~67% |
| Patients losing 15% or more | ~25% | ~49% |
Important context on these numbers: These results come from separate clinical trials with different durations. OASIS 4 ran 20 weeks longer than ATTAIN-1. Longer trials generally show more weight loss because patients have more time on the medication at full dose. No head-to-head trial between orforglipron and oral Wegovy exists as of April 2026.
That said, this result is consistent with the broader data pattern: semaglutide (Wegovy's active ingredient) has consistently outperformed GLP-1-only competitors in weight loss trials. The gap is real, even if the exact magnitude is hard to pin down without a direct comparison.
What About Blood Sugar Control?
Both medications improve blood sugar regulation through GLP-1 receptor activation. Semaglutide has extensive published data for type 2 diabetes management (as Ozempic and Rybelsus). Orforglipron's diabetes data is still emerging. If blood sugar management is a primary concern, discuss this specific factor with your provider.
The Convenience Factor
This is where orforglipron has a clear advantage — and for many patients, it may be the deciding factor.
Orforglipron: Take It Whenever
- Swallow the pill anytime — morning, afternoon, or evening
- Take it with food, without food, or with coffee
- No fasting window required
- No water volume restrictions
- Fits into any existing medication routine
Oral Wegovy: The 30-Minute Rule
- Take on an empty stomach first thing in the morning
- Swallow with no more than 4 ounces (120 mL) of plain water
- Wait at least 30 minutes before eating, drinking anything else, or taking other oral medications
- Must remain upright (no lying back down) during the fasting window
- Morning timing strongly recommended
For patients who take other morning medications, drink coffee first thing, or simply don't want to restructure their morning routine, this difference matters. The 30-minute fasting requirement is the same protocol as Rybelsus (oral semaglutide for diabetes) and has been a well-documented source of frustration and non-adherence.
Why does oral Wegovy require fasting? Semaglutide is a peptide — a type of protein — that gets broken down by stomach acid and food. The fasting window and water restriction protect the drug so enough of it gets absorbed. Orforglipron is a small molecule, not a peptide, which is why it survives the stomach without these restrictions.
How do orforglipron and oral Wegovy compare on price?
At self-pay prices, orforglipron saves $50-$150 per month — roughly $600-$1,800 per year. For patients paying cash, this is a significant and ongoing difference. But insurance changes the math entirely in some cases, particularly for Medicare patients.
| Orforglipron | Oral Wegovy | |
|---|---|---|
| Cash pay (self-pay) | ~$149/month | $199-$299/month |
| Annual cost (cash) | ~$1,788 | ~$2,388-$3,588 |
| With commercial insurance | TBD (newly launched) | $0-$150/month typical with savings card |
| Medicare | Check plan — coverage varies | Covered under TROA |
| Savings programs | Expected (Lilly typically offers) | Novo Nordisk savings card available |
| Annual savings (orf. vs oral Wegovy, cash) | — | $600-$1,800/year cheaper with orforglipron |
But insurance changes the math. If your plan already covers Wegovy (injectable or oral), your copay may be lower than orforglipron's cash price. Oral Wegovy benefits from Novo Nordisk's established payer relationships and savings card programs. Orforglipron, as a newly launched medication, is still building its insurance coverage network.
Medicare patients: Oral Wegovy has a meaningful advantage here. The Treat and Reduce Obesity Act (TROA) established Medicare coverage for anti-obesity medications, and Wegovy — as an established brand — has clear coverage pathways. Orforglipron's Medicare coverage is still being determined on a plan-by-plan basis.
Side Effects Compared
| Side Effect | Orforglipron | Oral Wegovy |
|---|---|---|
| Nausea | ~59% | ~47% |
| Diarrhea | ~22% | ~20% |
| Vomiting | ~14% | ~31% |
| Constipation | ~14% | ~16% |
| Abdominal pain | ~8% | ~8% |
| Discontinuation due to side effects | ~10% | ~7% |
The GI side effect story is not simple — each pill has a different profile.
Orforglipron causes more nausea (~59% vs ~47%). This is the most common complaint in ATTAIN-1 data. Most nausea occurs during dose escalation and tends to improve as the body adjusts, but the rate is notably higher than oral Wegovy.
Oral Wegovy causes more vomiting (~31% vs ~14%). This is a meaningful difference. Vomiting is generally considered more disruptive than nausea, and a 31% rate is high enough that patients should plan for it during titration.
Cross-trial comparison caveat: These side effect rates come from different trials with different populations and titration schedules. Rates in real-world clinical practice often differ from clinical trial data. Your individual experience may not match the averages.
What to expect in practice: Both medications escalate dosing gradually to reduce side effects. Most GI symptoms peak during dose increases and settle within 2-4 weeks at each new dose level. If you experience persistent or severe symptoms on either medication, your provider can adjust the titration schedule.
Insurance and Coverage
Orforglipron
- Commercial insurance: Coverage is building but inconsistent. As a newly launched medication, many plans have not yet added orforglipron to their formularies. Expect prior authorization requirements.
- Medicare: Plan-by-plan — not yet universally covered. Check with your specific Part D plan.
- Savings programs: Eli Lilly is expected to offer manufacturer savings cards, consistent with their approach to other medications.
- Self-pay advantage: At $149/month, orforglipron is designed to be affordable even without insurance — Lilly has positioned this as a core selling point.
Oral Wegovy
- Commercial insurance: Broader coverage than orforglipron. Many plans that already cover injectable Wegovy are extending coverage to oral Wegovy. Prior authorization is still common.
- Medicare: Covered under TROA provisions. This is a significant advantage for patients 65 and older.
- Novo Nordisk savings card: Available for eligible commercially insured patients, often reducing copays to $0-$25/month.
- Caveat: Even with "coverage," some plans impose step therapy requirements (try cheaper options first) or quantity limits.
Bottom line on coverage: If you have strong insurance coverage for Wegovy, oral Wegovy is likely your more affordable option despite its higher list price. If you're paying cash or have limited coverage, orforglipron's $149/month price is hard to beat.
Which should you choose: orforglipron or oral Wegovy?
When patients ask "orforglipron vs oral Wegovy which is better," the answer depends almost entirely on whether maximum weight loss or daily convenience matters more to you — and what your insurance covers.
Choose Orforglipron If:
- Price is a primary concern. At $149/month cash, orforglipron is $50-$150/month cheaper than oral Wegovy without insurance.
- You can't or won't do the 30-minute fasting window. If morning fasting conflicts with your routine, other medications, or your lifestyle, orforglipron removes that barrier completely.
- You take other morning medications. Oral Wegovy's fasting restriction means other oral medications must wait at least 30 minutes. Orforglipron has no such limitation.
- Flexibility on timing matters to you. Shift workers, frequent travelers, and anyone with an irregular schedule may find orforglipron easier to take consistently.
- You're comfortable with a newer medication. Orforglipron is awaiting FDA approval (expected April 2026) and would have less long-term real-world data than semaglutide.
Choose Oral Wegovy If:
- Maximum weight loss is your top priority. Oral Wegovy's ~16.6% weight loss is meaningfully higher than orforglipron's ~12.4% in trials.
- Your insurance already covers Wegovy. With a savings card, your out-of-pocket cost may be lower than orforglipron's cash price.
- You're on Medicare. Oral Wegovy has clearer Medicare coverage pathways under TROA.
- You're switching from injectable Wegovy. Same active ingredient (semaglutide), so your provider can manage a straightforward transition.
- You prefer a medication with more long-term data. Semaglutide has been studied and prescribed since 2017 (as Ozempic). Orforglipron is a new molecule with a shorter track record.
- Vomiting concerns you more than nausea. Orforglipron has higher nausea rates, but oral Wegovy has significantly higher vomiting rates. If vomiting is your bigger concern, orforglipron's profile may actually be preferable — weigh this with your provider.
When the Answer Isn't Clear
If you're genuinely torn, consider these tiebreakers:
- Check your insurance first. Coverage may make the decision for you. If one pill is covered and the other isn't, that's often the practical answer.
- Think about your morning routine. The fasting requirement is daily and permanent. Be honest about whether you'll follow it consistently.
- Discuss with your provider. Your medical history, other medications, and specific health conditions may make one option clinically preferable.
Can You Switch Between Them?
Yes, but with clinical supervision. Both are GLP-1 receptor agonists, so switching between them is pharmacologically reasonable. However:
- Oral Wegovy to orforglipron: Your provider will likely start you at orforglipron's introductory dose and re-titrate upward. You should not assume the weight loss you achieved on oral Wegovy will be maintained at the same level, since orforglipron produces less weight loss on average.
- Orforglipron to oral Wegovy: If your weight loss on orforglipron is insufficient, switching to oral Wegovy may improve results. Your provider will manage the semaglutide titration schedule from the beginning.
- Timing: There is no required washout period between these medications. Your provider will determine the appropriate transition plan based on your current dose and response.
Do not switch medications without consulting your prescriber. Both medications require dose titration, and skipping the ramp-up increases the risk of severe GI side effects.
Frequently Asked Questions
Are orforglipron and oral Wegovy the same drug?
No. They are different medications that target the same receptor (GLP-1). Oral Wegovy contains semaglutide — a peptide that mimics GLP-1. Orforglipron is a small molecule — a chemically different type of compound that also activates the GLP-1 receptor. Different drugs, same target, different efficacy and side effect profiles.
Which pill causes fewer side effects?
Neither is clearly "better" on side effects. Orforglipron has higher nausea rates (~59% vs ~47%). Oral Wegovy has higher vomiting rates (~31% vs ~14%). Overall discontinuation rates due to side effects are similar. Your individual response is difficult to predict from trial averages.
Can I take either pill with food?
Orforglipron: yes, with or without food, anytime. Oral Wegovy: no — it must be taken on an empty stomach with a small amount of plain water, followed by a 30-minute fast. This is a fundamental difference between the two medications.
Is orforglipron $149/month everywhere?
Eli Lilly has set the list price at $149/month for self-pay patients. Your actual cost depends on whether you're paying cash, using insurance, or accessing a savings program. Pharmacy pricing may vary slightly. This price applies to the medication itself and does not include provider consultation fees, which vary by telehealth platform.
Will my Wegovy insurance coverage transfer to oral Wegovy?
In many cases, yes — but not automatically. Oral Wegovy is a different formulation, and some plans require separate prior authorization. If you currently have injectable Wegovy approved, ask your provider to submit prior authorization for the oral version. The same active ingredient makes approval more likely, but not guaranteed.
Can I take orforglipron and oral Wegovy together?
No. Both target the GLP-1 receptor. Taking them together would increase side effects without established additional benefit. Your provider will prescribe one or the other.
Which is better for someone who's never taken a GLP-1 before?
Neither is universally better as a first GLP-1. If cost and convenience are your priority, orforglipron is a strong starting point. If maximum weight loss is your goal and you can manage the fasting protocol, oral Wegovy has stronger efficacy data. Discuss your specific situation — weight loss goals, budget, insurance, and medical history — with your provider.
I'm on injectable Wegovy. Should I switch to the pill?
Oral Wegovy may be an option if you want to stop injecting while staying on semaglutide. However, oral semaglutide has historically shown lower bioavailability than injectable semaglutide. Discuss with your provider whether the oral dose (25mg) provides comparable effect to your current injection dose. Do not switch without medical guidance.
Related Resources
- Orforglipron Complete Guide — Full clinical breakdown, trial data, and pricing for orforglipron
- Oral Semaglutide vs Injectable — How oral and injectable semaglutide compare
- Orforglipron vs Tirzepatide — Pill vs injection comparison from Eli Lilly's lineup
- Orforglipron vs Compounded Semaglutide — New pill vs compounded injections
- Oral GLP-1 Pills vs Injections — Broader oral vs injectable comparison
- Compounded Semaglutide vs Brand Wegovy — Cost comparison of semaglutide options
- Best GLP-1 Weight Loss Programs 2026 — All providers ranked